Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.51 |
| ▸ | BRD2 | P25440 | 2/20 | 0.50 |
| ▸ | IL17A | Q16552 | 1/20 | 0.50 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30052318 | 1.00 | BRD4 (0.55) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL15709319 | 0.92 | BRD4 (0.52) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL15709519 | 0.90 | BRD4 (0.51) | BRD4KDM4EALDH1A1MAPTBRD2 | |
| SCHEMBL30053201 | 0.89 | KDM4E (0.65) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL348420 | 0.89 | KDM4E (0.65) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL15709586 | 0.88 | BRD4 (0.50) | BRD4HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL378020 | 0.87 | BRD4 (0.58) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL348652 | 0.87 | BRD4 (0.58) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL30053496 | 0.87 | BRD4 (0.58) | BRD4KDM4EALDH1A1MAPTHDAC3 | |
| SCHEMBL378189 | 0.87 | BRD4 (0.57) | BRD4KDM4EALDH1A1MAPTHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | claimed |
| EP-3268007-B1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP (CA) | 2022-11-09 | — | — | EP | claimed |
| CN-114984016-A | Compositions and methods for treating complement-associated diseases | 雷斯韦洛吉克斯公司 | 2022-09-02 | — | — | CN | claimed |
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2019-03-28 | — | — | US | claimed |
| US-10131640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2018-11-20 | — | — | US | claimed |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | RESVERLOGIX CORP. (CA) | 2018-10-30 | — | — | US | claimed |
| EP-3268007-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | Resverlogix Corp. (CA) | 2018-01-17 | — | — | EP | claimed |
| WO-2016147053-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP. (CA) | 2016-09-22 | — | — | WO | claimed |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2016-09-15 | — | — | US | claimed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | claimed |
| WO-2013175281-A1 | USE OF SUBSTITUTED 2-PHENYL-3H-QUINAZOLIN-4-ONES AND ANALOGS FOR INHIBITING BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) PROTEINS | RVX THERAPEUTICS INC. (CA) | 2013-11-28 | — | — | WO | claimed |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| EP-3268007-B1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | RESVERLOGIX CORP (CA) | 2022-11-09 | — | — | EP | disclosed |
| CN-114984016-A | Compositions and methods for treating complement-associated diseases | 雷斯韦洛吉克斯公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | BRD4 700/4885KDM4E 3726/4885ALDH1A1 650/4885 |
| US-20130281399-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | BRD4 10/4885KDM4E 342/4885ALDH1A1 3920/4885 |
| US-10111885-B2 | Compositions and therapeutic methods for the treatment of complement-associated diseases | C5, CFH, C1QBP | BRD4 3811/4885KDM4E 3741/4885ALDH1A1 2199/4885 |
| US-10131640-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | BRD4 744/4885KDM4E 3982/4885ALDH1A1 587/4885 |
| US-20160263126-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885KDM4E 3741/4885ALDH1A1 2199/4885 |
| US-20190091235-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES | C5, CFH, C1QBP | BRD4 3811/4885KDM4E 3741/4885ALDH1A1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.